DNA binding chelates for nonviral gene delivery imaging

[1]  O. Zelphati,et al.  PNA-dependent gene chemistry: stable coupling of peptides and oligonucleotides to plasmid DNA. , 2000, BioTechniques.

[2]  D. Scherman,et al.  Novel method for covalent fluorescent labeling of plasmid DNA that maintains structural integrity of the plasmid. , 2000, Bioconjugate chemistry.

[3]  N. Chowdhury,et al.  Liver-directed gene therapy: promises, problems and prospects at the turn of the century. , 2000, Journal of hepatology.

[4]  R. Mahato.  Non-viral peptide-based approaches to gene delivery. , 1999, Journal of drug targeting.

[5]  W. Yung,et al.  Adenovirus-mediated p53 gene therapy for human gliomas. , 1999, Neurosurgery.

[6]  R. Weissleder,et al.  Targeting of green fluorescent protein expression to the cell surface. , 1999, Biochemical and biophysical research communications.

[7]  Felgner Pl.  Prospects for synthetic self-assembling systems in gene delivery. , 1999 .

[8]  Blasberg Rg,et al.  Herpes simplex virus thymidine kinase as a marker/reporter gene for PET imaging of gene therapy. , 1999 .

[9]  R. Ralston,et al.  Combination surgery and nonviral interleukin 2 gene therapy for head and neck cancer. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[10]  P. Scardino,et al.  In situ gene therapy for adenocarcinoma of the prostate: a phase I clinical trial. , 1999, Human gene therapy.

[11]  R. Blasberg,et al.  Herpes simplex virus thymidine kinase as a marker/reporter gene for PET imaging of gene therapy. , 1999, The quarterly journal of nuclear medicine : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology.

[12]  O. Zelphati,et al.  Gene chemistry: functionally and conformationally intact fluorescent plasmid DNA. , 1999, Human gene therapy.

[13]  B. Wollenberg,et al.  Gene therapy--phase I trial for primary untreated head and neck squamous cell cancer (HNSCC) UICC stage II-IV with a single intratumoral injection of hIL-2 plasmids formulated in DOTMA/Chol. , 1999, Human gene therapy.

[14]  R Weissleder,et al.  Novel gliosarcoma cell line expressing green fluorescent protein: A model for quantitative assessment of angiogenesis. , 1998, Microvascular research.

[15]  R. Herrmann,et al.  A phase I study of adenovirus-mediated wild-type p53 gene transfer in patients with advanced non-small cell lung cancer. , 1998, Human gene therapy.

[16]  P. Felgner.  DNA vaccines , 1998, Current Biology.

[17]  R. Weissleder,et al.  Mapping the in vivo distribution of herpes simplex virions. , 1998, Human gene therapy.

[18]  R. Weissleder,et al.  MR imaging of gene delivery to the central nervous system with an artificial vector. , 1998, Radiology.

[19]  R Weissleder,et al.  Design of metal-binding green fluorescent protein variants. , 1998, Biochimica et biophysica acta.

[20]  B. O'Malley,et al.  Combination Gene Therapy for Salivary Gland Cancer , 1998, Annals of the New York Academy of Sciences.

[21]  R Weissleder,et al.  The development of in vivo imaging systems to study gene expression. , 1998, Trends in biotechnology.

[22]  K. Zinn,et al.  Imaging and tissue biodistribution of 99mTc-labeled adenovirus knob (serotype 5) , 1998, Gene Therapy.

[23]  J. Wolff.  Naked DNA transport and expression in mammalian cells , 1997, Neuromuscular Disorders.

[24]  P. Winnard,et al.  Preparation and use of NHS-MAG3 for technetium-99m labeling of DNA. , 1997, Nuclear medicine and biology.

[25]  P. Felgner.  Nonviral strategies for gene therapy. , 1997, Scientific American.

[26]  M. Egholm,et al.  In vivo hybridization of technetium-99m-labeled peptide nucleic acid (PNA). , 1997, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[27]  Scott E. Fraser,et al.  A SMART MAGNETIC RESONANCE IMAGING AGENT THAT REPORTS ON SPECIFIC ENZYMATIC ACTIVITY , 1997 .

[28]  P. Cullis,et al.  Nomenclature for synthetic gene delivery systems. , 1997, Human gene therapy.

[29]  I. Wicks,et al.  Human gene therapy. , 1995, Australian and New Zealand journal of medicine.

[30]  F. Szoka,et al.  Mechanism of oligonucleotide release from cationic liposomes. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[31]  K. Mechtler,et al.  Activation of the complement system by synthetic DNA complexes: a potential barrier for intravenous gene delivery. , 1996, Human gene therapy.

[32]  F. Szoka,et al.  Mechanism of DNA release from cationic liposome/DNA complexes used in cell transfection. , 1996, Biochemistry.

[33]  F. Szoka,et al.  Characterization of plasmid DNA transfer into mouse skeletal muscle: evaluation of uptake mechanism, expression and secretion of gene products into blood. , 1996, Gene therapy.

[34]  F. Szoka,et al.  Intratracheal gene delivery to the mouse airway: characterization of plasmid DNA expression and pharmacokinetics. , 1995, Gene therapy.

[35]  F. Szoka,et al.  Intracellular oligonucleotide hybridization detected by fluorescence resonance energy transfer (FRET). , 1994, Nucleic acids research.

[36]  Pratik Ghosh,et al.  Nuclear Magnetic Resonance (NMR) Imaging of Iron Oxide-Labeled Neural Transplants , 1993, Experimental Neurology.

[37]  M. Palumbo,et al.  Sequence specificity of psoralen photobinding to DNA: a quantitative approach. , 1992, Biochemistry.

[38]  F. Szoka,et al.  Rapid nuclear accumulation of injected oligodeoxyribonucleotides. , 1990, The New biologist.

[39]  J. Hearst,et al.  Psoralen-deoxyribonucleic acid photoreaction. Characterization of the monoaddition products from 8-methoxypsoralen and 4,5'8-trimethylpsoralen. , 1982, Biochemistry.